Electroacupuncture as an add-on to SSRI treatment for generalized anxiety disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants with generalized anxiety disorder on a stable SSRI dose are randomized to receive electroacupuncture, sham electroacupuncture, or be placed on a waiting list, alongside continuing their SSRI. The trial uses the Hamilton Anxiety Rating Scale to measure changes in anxiety and includes an MRI-based sub-study to explore brain activity changes. The neuroimaging portion compares healthy controls and patients on SSRI therapy with and without active electroacupuncture. Outcomes focus on safety and clinical effectiveness over a defined treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Meet the DSM-5 diagnostic criteria for Generalized Anxiety Disorder (GAD).
* the patient has been taking the same anxiolytic medication consistently for 2 weeks prior to enrollment.
* HAMA score ≥ 14.
* Right-handed（for MRI).
* Aged 18-60 years, with at least primary school education.
* Signed informed consent.

Exclusion Criteria:

* Complicated with severe cardiovascular, cerebrovascular, or organic diseases.
* History of other psychiatric disorders (e.g., schizophrenia, bipolar disorder).
* Contraindications for MRI (e.g., metal implants, claustrophobia).
* Pregnancy or lactation.

Where it's running

• Affiliated Hangzhou First People's Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Lishu Gao
• Email: rodelo@sina.com
• Phone: +86 13858015836

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adjunctive JNJ-99245354 for Generalized Anxiety Disorder (GAD)

  This study tests whether adding JNJ-99245354 to existing GAD treatment helps reduce anxiety more than a placebo for adults with GAD who didn’t get adequate benefit from previous treatments.

  Recruiting at 4 sites Phase 3 Intra-Cellular Therapies, Inc. · Temecula, California and 3 other locations · NCT07856420

• Testing ITI-1284 for Generalized Anxiety Disorder (GAD)

  This phase 3 trial tests whether ITI-1284 is safe and tolerable when taken alone or with other medicines by adults with generalized anxiety disorder who haven’t responded to prior treatment.

  Recruiting at 3 sites Phase 3 Intra-Cellular Therapies, Inc. · Los Angeles, California and 2 other locations · NCT07807865

• Long-term safety and tolerability of SEP-363856 in adults with generalized anxiety disorder

  In adults with generalized anxiety disorder, this Phase 3 open-label extension tests whether continuing SEP-363856 at 50 mg or 75 mg daily for 26 weeks is safe, tolerable, and possibly helpful.

  Recruiting at 2 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Jacksonville, Florida and 1 other locations · NCT07786454

• Anxiety Skills Study: See if video skill training plus therapy helps people with anxiety

  This study tests whether a brief video-based skill training can help people with anxiety as well as four therapy sessions, and how durable the effects are over a year.

  Recruiting Ohio State University · Columbus, Ohio · NCT07774481

• Continuous Theta Burst Stimulation for Generalized Anxiety Disorder (cTBS for GAD)

  This study tests whether applying continuous theta burst stimulation to the right posterior parietal cortex or the right dorsolateral prefrontal cortex helps adults with generalized anxiety disorder.

  Recruiting Military Hospital 175 · Ho Chi Minh City · NCT07770919

• Fixed-dose SEP-363856 vs placebo for adults with generalized anxiety disorder

  This trial tests whether a fixed 75 mg/day dose of SEP-363856 helps adults with generalized anxiety disorder more than placebo over 8 weeks.

  Recruiting at 11 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Redlands, California and 10 other locations · NCT07767903

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.